JPMORGAN CHASE & CO - 30 Apr 2025 SCHEDULE 13G/A Report for KEROS THERAPEUTICS, INC. Common Stock, $0.0001 par value per share (KROS)

Filing Manager
JPMORGAN CHASE & CO
Reporting Manager
JPMORGAN CHASE & CO.
Security
KEROS THERAPEUTICS, INC. Common Stock, $0.0001 par value per share
Symbol
KROS
Disclosed Ownership
113,803 shares
Ownership
0.2%
Form type
SCHEDULE 13G/A
Filing time
05 May 2025, 14:03:05 UTC
Date of event
30 Apr 2025
Previous filing
02 May 2025
SEC
View on sec.gov

Quoteable Key Fact

"JPMORGAN CHASE & CO disclosed 0.2% ownership in KEROS THERAPEUTICS, INC. Common Stock, $0.0001 par value per share (KROS) on 30 Apr 2025."

Quick Takeaways

  • JPMORGAN CHASE & CO filed SCHEDULE 13G/A for KEROS THERAPEUTICS, INC. Common Stock, $0.0001 par value per share (KROS).
  • Disclosed ownership: 0.2%.
  • Date of event: 30 Apr 2025.

What Changed

  • Previous schedule filing date: 02 May 2025.
  • Current filing was accepted on 05 May 2025, 14:03.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (1)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
JPMORGAN CHASE & CO. 0.2% 113,803 113,803 0 Rachel Tsvaygoft Vice President
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .